🟢 Clearpoint Neuro Inc is trading 7% up today following positive FDA feedback for partner uniQure

Clearpoint Neuro Inc is trading 7% up today at $17.98, extending a powerful two-day rally driven by optimism surrounding partner uniQure’s Huntington’s disease treatment path.

• The move follows positive FDA feedback indicating that Phase I/II data for AMT-130 may support an accelerated BLA, highlighting the strategic value of Clearpoint’s neurosurgical platform.
• Shares are building on a sharp jump from the prior session as investors recognize the company's role in high-stakes clinical delivery systems.
• The ongoing rally underscores the market's positive outlook on Clearpoint’s specialized tools used in uniQure’s gene therapy trials.